Literature DB >> 9628872

The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus.

J E Strong1, M C Coffey, D Tang, P Sabinin, P W Lee.   

Abstract

NIH-3T3 cells, which are resistant to reovirus infection, became susceptible when transformed with activated Sos or Ras. Restriction of reovirus proliferation in untransformed NIH-3T3 cells was not at the level of viral gene transcription, but rather at the level of viral protein synthesis. An analysis of cell lysates revealed that a 65 kDa protein was phosphorylated in untransformed NIH-3T3 cells, but only after infection with reovirus. This protein was not phosphorylated in infected or uninfected transformed cells. The 65 kDa protein was determined to be the double-stranded RNA-activated protein kinase (PKR), whose phosphorylation leads to translation inhibition. Inhibition of PKR phosphorylation by 2-aminopurine, or deletion of the Pkr gene, led to drastic enhancement of reovirus protein synthesis in untransformed cells. The emerging picture is one in which early viral transcripts trigger PKR phosphorylation in untransformed cells, which in turn leads to inhibition of translation of viral genes; this phosphorylation event is blocked by an element(s) in the Ras pathway in the transformed cells, allowing viral protein synthesis to ensue. The usurpation of the Ras signaling pathway therefore constitutes the basis of reovirus oncolysis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9628872      PMCID: PMC1170673          DOI: 10.1093/emboj/17.12.3351

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  57 in total

1.  The 58,000-dalton cellular inhibitor of the interferon-induced double-stranded RNA-activated protein kinase (PKR) is a member of the tetratricopeptide repeat family of proteins.

Authors:  T G Lee; N Tang; S Thompson; J Miller; M G Katze
Journal:  Mol Cell Biol       Date:  1994-04       Impact factor: 4.272

Review 2.  Molecular mechanisms in the control of translation by hormones and growth factors.

Authors:  N T Redpath; C G Proud
Journal:  Biochim Biophys Acta       Date:  1994-01-13

3.  Membrane targeting of the nucleotide exchange factor Sos is sufficient for activating the Ras signaling pathway.

Authors:  A Aronheim; D Engelberg; N Li; N al-Alawi; J Schlessinger; M Karin
Journal:  Cell       Date:  1994-09-23       Impact factor: 41.582

4.  Identification of a conserved motif that is necessary for binding of the vaccinia virus E3L gene products to double-stranded RNA.

Authors:  H W Chang; B L Jacobs
Journal:  Virology       Date:  1993-06       Impact factor: 3.616

5.  Recognition of the epidermal growth factor receptor by reovirus.

Authors:  D Tang; J E Strong; P W Lee
Journal:  Virology       Date:  1993-11       Impact factor: 3.616

6.  Evidence that the epidermal growth factor receptor on host cells confers reovirus infection efficiency.

Authors:  J E Strong; D Tang; P W Lee
Journal:  Virology       Date:  1993-11       Impact factor: 3.616

7.  The E3L and K3L vaccinia virus gene products stimulate translation through inhibition of the double-stranded RNA-dependent protein kinase by different mechanisms.

Authors:  M V Davies; H W Chang; B L Jacobs; R J Kaufman
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

8.  Desensitization of Ras activation by a feedback disassociation of the SOS-Grb2 complex.

Authors:  S B Waters; K H Holt; S E Ross; L J Syu; K L Guan; A R Saltiel; G A Koretzky; J E Pessin
Journal:  J Biol Chem       Date:  1995-09-08       Impact factor: 5.157

9.  2-Aminopurine inhibits the double-stranded RNA-dependent protein kinase both in vitro and in vivo.

Authors:  Y Hu; T W Conway
Journal:  J Interferon Res       Date:  1993-10

10.  Reversal of the interferon-sensitive phenotype of a vaccinia virus lacking E3L by expression of the reovirus S4 gene.

Authors:  E Beattie; K L Denzler; J Tartaglia; M E Perkus; E Paoletti; B L Jacobs
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

View more
  201 in total

1.  Reovirus as a novel oncolytic agent.

Authors:  K L Norman; P W Lee
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

2.  REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer.

Authors:  Charles Comins; James Spicer; Andrew Protheroe; Victoria Roulstone; Katie Twigger; Christine M White; Richard Vile; Alan Melcher; Matt C Coffey; Karl L Mettinger; Gerard Nuovo; David E Cohn; Mitch Phelps; Kevin J Harrington; Hardev S Pandha
Journal:  Clin Cancer Res       Date:  2010-10-06       Impact factor: 12.531

Review 3.  Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates.

Authors:  Guido Wollmann; Koray Ozduman; Anthony N van den Pol
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

4.  A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report.

Authors:  E Anders Kolb; Valerie Sampson; Deborah Stabley; Alexa Walter; Katia Sol-Church; Timothy Cripe; Pooja Hingorani; Charlotte Hsieh Ahern; Brenda J Weigel; James Zwiebel; Susan M Blaney
Journal:  Pediatr Blood Cancer       Date:  2015-02-27       Impact factor: 3.167

5.  Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors.

Authors:  Guido Wollmann; Eugene Drokhlyansky; John N Davis; Connie Cepko; Anthony N van den Pol
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

6.  Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies.

Authors:  Eleni M Karapanagiotou; Victoria Roulstone; Katie Twigger; Mercel Ball; Maryanne Tanay; Chris Nutting; Kate Newbold; Martin E Gore; James Larkin; Konstantinos N Syrigos; Matt Coffey; Brad Thompson; Karl Mettinger; Richard G Vile; Hardev S Pandha; Geoff D Hall; Alan A Melcher; John Chester; Kevin J Harrington
Journal:  Clin Cancer Res       Date:  2012-02-07       Impact factor: 12.531

Review 7.  Reovirus: a targeted therapeutic--progress and potential.

Authors:  Radhashree Maitra; Mohammad H Ghalib; Sanjay Goel
Journal:  Mol Cancer Res       Date:  2012-10-04       Impact factor: 5.852

8.  Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults.

Authors:  Kimberly P Kicielinski; E Antonio Chiocca; John S Yu; George M Gill; Matt Coffey; James M Markert
Journal:  Mol Ther       Date:  2014-02-20       Impact factor: 11.454

9.  Oncolytic reovirus effectively targets breast cancer stem cells.

Authors:  Paola Marcato; Cheryl A Dean; Carman A Giacomantonio; Patrick W K Lee
Journal:  Mol Ther       Date:  2009-03-17       Impact factor: 11.454

Review 10.  Ras oncogenes: split personalities.

Authors:  Antoine E Karnoub; Robert A Weinberg
Journal:  Nat Rev Mol Cell Biol       Date:  2008-07       Impact factor: 94.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.